- Home
- TNON vs SNGX Comparison
TNON vs SNGX Comparison
Compare TNON & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNON
- SNGX
- Stock Information
- Founded
- TNON 2012
- SNGX 1987
- Country
- TNON United States
- SNGX United States
- Employees
- TNON N/A
- SNGX N/A
- Industry
- TNON Medical Specialities
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- TNON Health Care
- SNGX Health Care
- Exchange
- TNON Nasdaq
- SNGX Nasdaq
- Market Cap
- TNON 6.7M
- SNGX 7.4M
- IPO Year
- TNON 2022
- SNGX 1987
- Fundamental
- Price
- TNON $1.79
- SNGX $2.35
- Analyst Decision
- TNON Strong Buy
- SNGX
- Analyst Count
- TNON 2
- SNGX 0
- Target Price
- TNON $16.00
- SNGX N/A
- AVG Volume (30 Days)
- TNON 153.6K
- SNGX 619.7K
- Earning Date
- TNON 03-11-2025
- SNGX 03-14-2025
- Dividend Yield
- TNON N/A
- SNGX N/A
- EPS Growth
- TNON N/A
- SNGX N/A
- EPS
- TNON N/A
- SNGX N/A
- Revenue
- TNON $3,315,000.00
- SNGX $364,183.00
- Revenue This Year
- TNON $29.03
- SNGX N/A
- Revenue Next Year
- TNON $100.29
- SNGX $76.64
- P/E Ratio
- TNON N/A
- SNGX N/A
- Revenue Growth
- TNON 38.30
- SNGX N/A
- 52 Week Low
- TNON $1.65
- SNGX $1.83
- 52 Week High
- TNON $15.79
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- TNON 39.49
- SNGX 34.04
- Support Level
- TNON $1.65
- SNGX $2.03
- Resistance Level
- TNON $2.30
- SNGX $3.44
- Average True Range (ATR)
- TNON 0.16
- SNGX 0.33
- MACD
- TNON 0.01
- SNGX -0.08
- Stochastic Oscillator
- TNON 21.57
- SNGX 19.39
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants, and 3) SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).